Available for comment on peptide regulation and evidence.

• Provide plainly-worded quotes for attribution.
• Source-check your draft against primary literature and regulatory filings.
• Point you at the relevant FDA Warning Letters, Federal Register filings, or trial publications — with direct URLs.
• Flag what we think you're missing or misreading.
• Honor embargoes.

• Comment on products we have an affiliate relationship with — we'll tell you up front and decline.
• Provide exclusive quotes to vendor-funded trade publications.
• Speak outside our beat (we cover peptide regulation + clinical evidence, not broader metabolic medicine, not health policy writ large).

• FDA compounding pharmacy regulation. Section 503A vs 503B, Category 1/2/3 bulk substances list, shortage-resolution discretion windows, warning letters, PCAC advisory committee process.
• GLP-1 receptor agonist clinical evidence. STEP, SURMOUNT, SURPASS, SELECT, SURMOUNT-5 head-to-head, REDEFINE-1/2, TRIUMPH program, ATTAIN (orforglipron) — trial design, endpoints, and what the data actually shows vs what it is claimed to show.
• Research peptide market dynamics. Vendor ecosystem, COA (Certificate of Analysis) publication norms, HPLC purity testing, FDA warning letter enforcement patterns, Trustpilot and r/Peptides crowd-sourced reputation signals.
• The February 2026 HHS peptide reclassification proposal. 14 peptides proposed for Category 2 removal, procedural path through PCAC + FDA, the July 2026 advisory committee hearing, political context, what approval/rejection means for patients.
• GLP-1 side effects beyond weight loss. Muscle and bone mass loss, rebound weight gain after discontinuation, rare adverse events (non-arteritic anterior ischemic optic neuropathy signal, pancreatitis, thyroid C-cell tumor boxed warning), psychiatric signals.
• Telehealth GLP-1 market transition. Compounded semaglutide wind-down, migration to branded Wegovy/Zepbound, NovoCare + LillyDirect direct-to-patient programs, telehealth provider landscape (Hims, Ro, Henry Meds, MEDVi).
• Peptide therapeutics in development. Retatrutide (triple GIP/GLP-1/glucagon), CagriSema, orforglipron (oral GLP-1), amycretin, survodutide, pemvidutide — pipeline status, mechanistic differentiation, regulatory timelines.

1. Acknowledgment within 4 business hours (ET).
2. Initial response with a framing of what we can and can't say on your topic within 24 hours.
3. Quotes for attribution within 48 hours of first contact if the story aligns with our beat.
4. We will ask you: what's the angle, who else is being quoted, and what's the deadline. Helps us calibrate.

The Peptide Examiner is an independent editorial publication covering peptide science, GLP-1 receptor agonists, and FDA regulatory action. Our editorial policy spells out sourcing hierarchy, evidence tier labels, AI-drafting rules, corrections process, and affiliate disclosure norms.

We use editorial review, not medical review — no named PharmD reviewer is currently on staff. Retaining one is a near-term priority. For stories where clinician-level review matters, we'll refer you to domain experts we trust.